$ACET (Aceto Corp.)

$ACET {{ '2016-08-26T17:56:16+0000' | timeago}} • Announcement

$ACET said its BoD has increased its regular quarterly dividend by 8.3% to $0.065 per common share. The dividend will be distributed on Sept. 20, 2016 to shareholders of record as of Sept. 9, 2016.

$ACET {{ '2017-06-20T14:58:15+0000' | timeago}} • Announcement

$ACET said its finished dosage form generics subsidiary Rising Pharmaceuticals has launched Glipizide Extended Release Tablets, an FDA-approved generic version of the reference listed drug, Glucotrol XL from $PFE. Glipizide are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

$ACET {{ '2017-06-20T14:56:43+0000' | timeago}} • Announcement

$ACET said its finished dosage form generics subsidiary Rising Pharmaceuticals has launched an FDA-approved generic version of Chlorthalidone Tablets, 25 mg and 50 mg, which are indicated for the management of hypertension.

$ACET {{ '2017-05-05T17:41:05+0000' | timeago}} • Webcast

$ACET’s DSOs increased during 3Q17 and some of it was related to the company’s rising business including the new elements of Citron and Lucid. Additionally, the company’s other segments also increased because of the timing of the sales. Currently on a TTM basis, $ACET is north of 100 days and expects it to come down in the non-generic business.

$ACET {{ '2017-05-05T14:44:49+0000' | timeago}} • Announcement

In 3Q17, $ACET's Human Health segment sales were $99.8MM, an increase of 69.8%, while Pharmaceutical Ingredients segment sales were $43.8MM, down 4.4%. Sales in Performance Chemicals segment declined 12.8% to $46.5MM.

$ACET {{ '2017-05-05T14:40:25+0000' | timeago}} • Announcement

Higher costs played dampener to $ACET's 3Q17 earnings, which halved despite a 20% growth in net sales to $190.1MM. Net income was $5.6MM, or $0.16 per share, compared to $10.4MM, or $0.35 per share in the year-over quarter. On an adjusted basis, $ACET earned $0.39 per share.

$ACET {{ '2017-05-04T19:10:23+0000' | timeago}} • Announcement

$ACET's BoD declared a regular quarterly cash dividend of $0.065 per common share. This dividend will be distributed on June 23, 2017 to shareholders of record as of June 9, 2017.

$ACET {{ '2017-02-03T14:43:56+0000' | timeago}} • Announcement

During 2Q17, $ACET's Human Health segment sales fell 8.6% YoY to $54MM, mainly due to increased competition and price erosion on certain products at Rising. Pharmaceutical Ingredients segment sales rose 7.4% to $36.8MM, helped by higher volumes of intermediates sold abroad. Performance Chemicals segment sales fell 9.3% YoY to $34.8MM.

$ACET {{ '2017-02-03T14:41:54+0000' | timeago}} • Announcement

Pharmaceutical intermediates and ingredients developer $ACET reported 2Q17 net loss of $0.56MM, or $0.02 per share, compared to net income of $8.27MM, or $0.28 per share in 2Q16. Excluding items, $ACET earned $0.24 per share, down 33.3% from $0.36 in 2Q16. Net sales fell 4.6% YoY to $125.6MM.

$ACET {{ '2017-02-02T20:55:31+0000' | timeago}} • Announcement

$ACET appointed Vimal Kavuru to its BoD, effective Feb. 2, 2017. Since 2013, Kavuru has been the CEO and a founder of Citron Pharma LLC and Lucid Pharma LLC, from which Aceto subsidiary Rising Pharmaceuticals acquired certain generic products and related assets in December 2016.

$ACET {{ '2017-02-02T20:27:58+0000' | timeago}} • Announcement

$ACET's BoD declared a regular quarterly dividend of $0.065 per common share. This dividend will be payable on March 24, 2017 to shareholders of record as of March 10, 2017.

$ACET {{ '2016-12-21T15:03:42+0000' | timeago}} • Announcement

$ACET completed, through its subsidiary Rising Pharmaceuticals, the acquisition of generic products and related assets of Citron Pharma LLC and its affiliate Lucid Pharma LLC. The total consideration, prior to any potential earn-out payments, is about $429MM, or $349MM, net of about $80MM of expected tax benefits.

$ACET {{ '2016-12-01T19:25:56+0000' | timeago}} • Announcement

$ACET's BoD declared a regular quarterly dividend of $0.065 per common share, payable on Dec. 22, 2016 to shareholders of record as of Dec. 12, 2016.

$ACET {{ '2016-11-18T13:49:10+0000' | timeago}} • Announcement

$ACET said Rising Pharmaceuticals, its finished dosage form generics subsidiary, is launching Erythromycin and Benzoyl Peroxide Topical Gel USP, an FDA-approved generic version of Valeant International’s Benzamycin Gel.

$ACET {{ '2016-09-16T14:57:33+0000' | timeago}} • Announcement

Rising Pharmaceuticals, Inc., a generics subsidiary of $ACET, is unveiling its Fluocinolone Acetonide OTIC Oil, an FDA approved generic version of Hill Dermaceuticals Inc.'s DermOtic. This product is used in the treatment of chronic eczematous external otitis, an inflammatory condition of ear canal.

$ACET {{ '2016-09-07T14:50:47+0000' | timeago}} • Announcement

$ACET said it appointed William Kennally III, to its BoD, effective Sept. 6, 2016. In 2010, Kennally became Regional President North America, Global Established Products for $PFE, and prior to his retirement in 2015 was Regional President North America Advisor, Global Established Pharma with Pfizer.

$ACET {{ '2016-08-26T17:56:16+0000' | timeago}} • Announcement

$ACET said its BoD has increased its regular quarterly dividend by 8.3% to $0.065 per common share. The dividend will be distributed on Sept. 20, 2016 to shareholders of record as of Sept. 9, 2016.

$ACET {{ '2016-08-26T15:25:22+0000' | timeago}} • Webcast

Cingular Research's analyst Greg Dyson asks what would be the implementation costs for the ERP project. $ACET CFO Douglas Roth said that the entire project cost would be about $2MM.

$ACET {{ '2016-08-26T14:58:34+0000' | timeago}} • Webcast

Matthew Hewitt of Craig-Hallum Capital asks about the M&A opportunities. CEO Salvatore Guccione said that $ACET is not just looking on the companies, but more on the product lines. The company has the money and it will be actively looking for M&A opportunities this year, the CEO said.

$ACET {{ '2016-08-26T14:45:37+0000' | timeago}} • Webcast

Matthew Hewitt of Craig-Hallum Capital asks the reason for the delay in new product launches. CEO Salvatore Guccione said that $ACET generally doesn't manufacture products. He added that the delay happens at the contract manufacturing organization level due to failure in testing and unavailability of equipments.

$ACET {{ '2016-08-26T14:13:31+0000' | timeago}} • Webcast

$ACET said that 4Q16 was a more challenging quarter compared to the prior year quarter. The company recorded an unanticipated $1.3MM charge related to the remediation work at its Arsynco property. $ACET has 103 total projects in its development pipeline, including 47 ANDAs currently on file with the FDA.

Recent Transcripts

IRBT (iRobot Corporation)
Wednesday, July 26 2017 - 12:30pm
CSL (Carlisle Companies Incorporated)
Tuesday, July 25 2017 - 9:00pm
HNI (HNI Corp.)
Tuesday, July 25 2017 - 3:00pm
ABG (Asbury Automotive Group, Inc.)
Tuesday, July 25 2017 - 2:00pm
AYI (Acuity Brands, Inc.)
Thursday, June 29 2017 - 2:00pm
OMN (OMNOVA Solutions Inc.)
Wednesday, June 28 2017 - 3:00pm
RAVN (Raven Industries Inc.)
Tuesday, May 23 2017 - 2:00pm
IOSP (Innospec Inc.)
Wednesday, May 10 2017 - 12:30pm
HEAR (Turtle Beach Corporation)
Tuesday, May 9 2017 - 9:00pm
DEPO (DepoMed Inc.)
Tuesday, May 9 2017 - 8:30pm
BCPC (Balchem Corp)
Tuesday, May 9 2017 - 3:00pm
ACET (Aceto Corp.)
Friday, May 5 2017 - 1:00pm
AVD (American Vanguard Corp.)
Thursday, May 4 2017 - 8:30pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
CLX (The Clorox Company)
Wednesday, May 3 2017 - 5:30pm
USNA (USANA Health Sciences Inc.)
Wednesday, May 3 2017 - 3:00pm
VRTV (Veritiv Corporation)
Wednesday, May 3 2017 - 2:00pm
IPHS (Innophos Holdings Inc)
Tuesday, May 2 2017 - 1:00pm
KWR (Quaker Chemical Corporation)
Tuesday, May 2 2017 - 12:30pm
MHK (Mohawk Industries Inc.)
Friday, April 28 2017 - 3:00pm

AlphaGraphics you may like